Athersys, Inc. (NASDAQ:ATHX) has been assigned an average broker rating score of 1.00 (Strong Buy) from the one analysts that cover the company, Zacks Investment Research reports. One research analyst has rated the stock with a strong buy recommendation.
Analysts have set a 1 year consensus target price of $11.00 for the company and are expecting that the company will post ($0.07) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Athersys an industry rank of 58 out of 255 based on the ratings given to related companies.
Separately, Dawson James started coverage on Athersys in a report on Monday, August 26th. They issued a “buy” rating and a $11.00 price objective for the company.
ATHX stock traded up $0.03 on Friday, reaching $1.33. The company’s stock had a trading volume of 419,113 shares, compared to its average volume of 585,768. Athersys has a 52 week low of $1.20 and a 52 week high of $2.15. The company has a market capitalization of $208.37 million, a P/E ratio of -7.39 and a beta of 0.34. The firm has a fifty day moving average of $1.33 and a two-hundred day moving average of $1.46.
Athersys (NASDAQ:ATHX) last issued its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.08). Athersys had a negative return on equity of 131.22% and a negative net margin of 458.03%. The business had revenue of ($0.36) million during the quarter, compared to analyst estimates of $1.51 million. Research analysts anticipate that Athersys will post -0.31 earnings per share for the current fiscal year.
In related news, COO William Lehmann, Jr. sold 30,000 shares of the stock in a transaction that occurred on Wednesday, September 18th. The stock was sold at an average price of $1.44, for a total value of $43,200.00. Following the completion of the transaction, the chief operating officer now directly owns 542,196 shares of the company’s stock, valued at approximately $780,762.24. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 15.31% of the company’s stock.
A number of hedge funds have recently modified their holdings of the stock. BlackRock Inc. grew its holdings in Athersys by 30.0% in the 2nd quarter. BlackRock Inc. now owns 9,797,005 shares of the biopharmaceutical company’s stock worth $16,459,000 after buying an additional 2,260,279 shares in the last quarter. Vanguard Group Inc. lifted its position in Athersys by 3.4% in the second quarter. Vanguard Group Inc. now owns 6,322,040 shares of the biopharmaceutical company’s stock worth $10,621,000 after purchasing an additional 205,334 shares during the period. Prudential PLC lifted its position in Athersys by 0.3% in the second quarter. Prudential PLC now owns 4,223,097 shares of the biopharmaceutical company’s stock worth $8,446,000 after purchasing an additional 11,200 shares during the period. State Street Corp lifted its position in Athersys by 3.9% in the third quarter. State Street Corp now owns 2,332,227 shares of the biopharmaceutical company’s stock worth $3,102,000 after purchasing an additional 87,101 shares during the period. Finally, Renaissance Technologies LLC lifted its position in Athersys by 31.6% in the second quarter. Renaissance Technologies LLC now owns 1,027,326 shares of the biopharmaceutical company’s stock worth $1,726,000 after purchasing an additional 246,976 shares during the period. 21.37% of the stock is owned by institutional investors and hedge funds.
Athersys, Inc, a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions.
Recommended Story: Special Dividends
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Athersys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athersys and related companies with MarketBeat.com's FREE daily email newsletter.